- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk | 382 | Business Wire | Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction... ► Artikel lesen | |
| Mi | IN BRIEF: Daiichi Sankyo, AstraZeneca start phase 3 Datroway trial | 6 | Alliance News | ||
| Mo | Daiichi Sankyo promotes Ken Keller to lead new commercialization unit | 17 | FiercePharma | ||
| DAIICHI SANKYO CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization | 357 | Business Wire | Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within... ► Artikel lesen | |
| 20.08. | Studienerfolg bei Partner Merck treibt Aktie von Daiichi Sankyo an | 39 | Investing.com Deutsch | ||
| 17.08. | Enhertu: AstraZeneca und Daiichi Sankyo melden Erfolg in Phase-3-Studie bei Lungenkrebs | 10 | Investing.com Deutsch | ||
| 12.08. | Daiichi, AstraZeneca drug Enhertu wins further approval in China | 7 | Alliance News | ||
| 12.08. | Daiichi Co Ltd Profit Rises In Nine Months | 5 | RTTNews | ||
| 11.08. | SOCOTEC entwickelt moderne Arbeitswelten für Daiichi Sankyo | 8 | DEAL-Magazin | ||
| 10.08. | Innovent and Daiichi Sankyo sign deal for Vanflyta in China | 7 | Pharmaceutical Technology | ||
| 10.08. | Innovent Biologics Secures China Commercialization Rights For Vanflyta In Deal With Daiichi Sankyo | 481 | AFX News | BEIJING (dpa-AFX) - Innovent Biologics Inc. (IVBXF, 1801.HK) and Daiichi Sankyo (DSKYF, 4568.T) have entered into an exclusive agreement for the commercialization of Vanflyta (quizartinib) in... ► Artikel lesen | |
| 07.08. | Daiichi Life Group Earnings Up In Q1; Maintains FY27 Outlook | 403 | AFX News | TOKYO (dpa-AFX) - Daiichi Life Group, Inc. (8750.T, DLICY), a Japanese insurance holding company, on Friday reported higher net income in the first quarter compared with the previous year. For... ► Artikel lesen | |
| 04.08. | DAIICHI Kensetsu Corp. Q1 Sales Increase | 13 | RTTNews | ||
| 31.07. | Daiichi Sankyo Q1 FY2026 slides: ADC growth masks margin pressure | 27 | Investing.com | ||
| 31.07. | Daiichi Sankyo flags accounting error, as shares tank despite revenue beat | 24 | FiercePharma | ||
| 31.07. | AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer | 5 | Seeking Alpha | ||
| 31.07. | Daiichi Sankyo Company reports Q1 results | 12 | Seeking Alpha | ||
| 31.07. | AstraZeneca's and Daiichi's Datroway wins EU breast cancer approval | 9 | Alliance News | ||
| 31.07. | Daiichi Jitsugyo Co Ltd Profit Rises In Q1 | 11 | RTTNews | ||
| 31.07. | Daiichi Sankyo: Datroway Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy | 535 | Business Wire | Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary... ► Artikel lesen |
1 2 3 4 5 Weiter >>
125 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,075 | -0,23 % | Gewinner der Börsengeschichte: Nicht Pfizer: Diese US-Pharma-Aktie schlägt mit +4.693.845 % Rendite sogar Exxon | © Foto: DALLE (KI-Bild) - OpenAIPharma schlägt Öl: Eine Studie zu 29.078 US-Aktien zeigt, dass CVS Health im Zeitraum von 1928 bis 2023 eine höhere Gesamtrendite erzielte als Exxon. Die Hintergründe... ► Artikel lesen | |
| GILEAD SCIENCES | 125,60 | -0,11 % | AWSX der Telegram-Trader.de: Gilead:Trodelvy bekommt in Europa deutlich mehr Gewicht-Wo liegen die Kursziele? | ||
| VIATRIS | 14,192 | +0,60 % | Citizens reiterates Opus Genetics stock rating on Viatris partnership potential | ||
| BIONANO GENOMICS | 1,170 | 0,00 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 211,90 | +0,38 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases | DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable... ► Artikel lesen | |
| DAIICHI SANKYO | 15,438 | -0,69 % | New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk | Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 7,100 | +1,43 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 463,70 | +0,56 % | Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off | ||
| OPUS GENETICS | 3,180 | -0,62 % | Opus Genetics: Citizens bestätigt Rating und sieht Potenzial durch Viatris-Partnerschaft | ||
| SAVARA | 4,533 | -3,68 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 3,100 | +1,47 % | H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 | ||
| BIOHAVEN | 13,765 | +3,50 % | Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing... ► Artikel lesen | |
| SKYE BIOSCIENCE | 1,700 | -0,25 % | XFRA NEW INSTRUMENTS AVAILABLE ON 24.08.2026 | The following instruments on XETRA do have their first trading 24.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.08.2026
Aktien
1 CA0966311064 Boardwalk Real Estate... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY | 1,325 | 0,00 % | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial | 90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated... ► Artikel lesen | |
| BAYER | 48,670 | +0,39 % | Bayer-Aktie: Score 1 - Warum das Rekordurteil nichts ändert - Warren Wise Podcast | Ein Risiko weniger ist noch keine Rendite: Der Oberste US-Gerichtshof hat im langen Glyphosat-Streit zugunsten von Bayer entschieden. Die Aktie sprang daraufhin deutlich nach oben. Trotzdem steht Bayer... ► Artikel lesen |
Das Unternehmen DAIICHI SANKYO CO LTD ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 14,800 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAIICHI SANKYO CO LTD ADR finden Sie auf Wallstreet Online.